Amgen’s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

Posted byZacks Equity Research Leave a comment on Amgen’s (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

Amgen’s (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

Leave a comment

Your email address will not be published. Required fields are marked *